Analyst Price Target is $11.00
▲ +1,230.75% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Kezar Life Sciences in the last 3 months. The average price target is $11.00, with a high forecast of $20.00 and a low forecast of $2.00. The average price target represents a 1,230.75% upside from the last price of $0.83.
Current Consensus is
The current consensus among 4 contributing investment analysts is to hold stock in Kezar Life Sciences. This Hold consensus rating has held steady for over two years.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.